Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels
Status:
Completed
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The objectives of this study is to perform CYP2D6 genotyping and metabolite concentrations
analysis on ER+ breast cancer patients who are taking tamoxifen and give dose recommendations
based on the CYP2D6 genotypes and endoxifen levels.